(Q47331075)

English

Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction

scientific article published in June 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction (English)

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Glick A

1

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

Kornowski R

2

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

Michowich Y

3

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

Koifman B

4

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

Roth A

5

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

Laniado S

6

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

Keren G

7

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

language of work or name

0 references

publication date

1 June 1996

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

American Journal of Cardiology

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

77

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

14

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

1145-1148

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Effect of coronary reocclusion after initial reperfusion on ventricular function and infarct size.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Platelets and thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Persistent activation of coagulation mechanism in unstable angina and myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommitte

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Reactivation of unstable angina after the discontinuation of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Reocclusion three months after successful thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activating complex

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Left ventricular function at 3 months after successful thrombolysis. Impact of reocclusion without reinfarction on ejection fraction, regional function, and remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Are we mortgaging the medical profession?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900152-X

7 January 2021

Identifiers

10.1016/S0002-9149(96)00152-X

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

release_3bfnuzu4xfbllp2ns6j2tx67sa

1 reference

https://api.fatcat.wiki/v0/release/3bfnuzu4xfbllp2ns6j2tx67sa

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/8651085

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47331075&oldid=2152367082"